CTOs on the Move

Rafael Pharmaceuticals

www.rafaelpharma.com

 
We are a pioneering, clinical-stage, metabolic oncology therapeutics company, focused on transforming the lives of patients with hard to treat cancers by applying our deep understanding of the unique bio-energetic processes specific to cancer.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Similar Companies

Vetagro

Vetagro is a company that specializes in feed additive development and production for the animal feed industry. They focus on developing targeted solutions through scientific research, technological development, innovative formulation, and a focus on q...

CNS Healthcare

Providing mental health and substance use disorder services for children, youth, and adults. No insurance needed. #EndStigma

Columbus Prescription Pharmacies

Columbus Prescription Pharmacies, Inc. is a Columbus, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Wellinks

Wellinks is a virtual COPD management solution empowering members to live fully, and breathe freely.

Paratek Pharmaceuticals

Paratek Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of antibacterial therapeutics based upon tetracycline chemistry in the United States. Its lead product candidate, omadacycline, is a tetracycline-derived and broad-spectrum antibiotic developed in oral tablet and intravenous formulations for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CABP), urinary tract infections, and other serious community-acquired bacterial infections. The company has special protocol assessment agreements with Food and Drug Administration for the Phase III trials planned in ABSSSI and CABP. It is also developing sarecycline, a tetracycline-derived compound that is in Phase III clinical trials for use in the treatment of acne and rosacea. The company has collaborative research and license agreement with Actavis to research, develop, and commercialize tetracycline products; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and collaboration agreement with Purdue Pharmaceuticals L.P. to commercialize Intermezzo. Paratek Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts.